butabarbital decreases outcomes of sufentanil SL by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Carefully. Coadministration of CYP3A4 inducers could minimize sufentanil concentrations and efficacy, potentially precipitating withdrawal syndrome in clients who have